Lynkuet vs Veozah: Comparing the Two Non-Hormonal Hot Flash Pills

Both Lynkuet and Veozah work by quieting a specific group of neurons in the brain that lose their off switch when estrogen declines. They do not replace estrogen, and they do not act on estrogen receptors anywhere in the body.

Deep in the hypothalamus sits a cluster of cells called KNDy neurons — named for the three signalling molecules they use: kisspeptin, neurokinin B, and dynorphin. These neurons sit right next to the brain's thermoregulatory centre, the internal thermostat. In the reproductive years, estrogen keeps KNDy neurons in check.

When estrogen falls in perimenopause and menopause, that brake comes off. KNDy neurons enlarge and become hyperactive, flooding the neighbouring thermostat with neurokinin B. The thermostat misreads this as "you are overheating" and triggers the full heat-dumping cascade: blood vessels in the skin dilate, you flush, you sweat, and then you get the chill afterwards as your body overcorrects. That is a hot flash — technically a vasomotor symptom, or VMS.

Neurokinin B delivers its message by docking onto NK3 receptors. Block those receptors and the false overheating signal never lands. That is the entire mechanism, and it is a genuinely elegant piece of drug design: rather than replacing the hormone, it interrupts the specific downstream signal that hormone loss unleashes.

This matters enormously for women who cannot take hormones — those with a history of breast cancer, blood clots, or stroke — and for women who simply prefer not to. Until 2023 their options were largely off-label antidepressants, gabapentin, and behavioural approaches like [CBT for menopause](/blog/cbt-for-menopause-nice-recommended-nonhormonal-treatment) and [hypnotherapy for hot flashes](/blog/hypnotherapy-for-hot-flashes-does-it-actually-work). Both remain genuinely useful. But having two targeted drugs is a different landscape entirely.

The core difference is how many receptors each drug blocks. Veozah targets NK3 alone. Lynkuet targets NK1 and NK3 together, which is why it addresses sleep in a way Veozah does not directly claim.

Veozah (fezolinetant) was approved by the FDA in May 2023 as the first neurokinin-targeted therapy for moderate to severe vasomotor symptoms due to menopause. It is a selective NK3 receptor antagonist, taken as a 45 mg tablet once daily. Its pivotal evidence comes from the SKYLIGHT 1, 2 and 4 trials.

Lynkuet (elinzanetant) received FDA approval on October 24, 2025, making it the second drug in the class and the first and only dual NK1 and NK3 receptor antagonist. It is a 60 mg capsule taken once daily, and its approval rests on the OASIS 1, 2 and 3 phase 3 programme.

The NK1 addition is not cosmetic. NK1 receptors are bound by substance P, a neuropeptide involved in sleep architecture, mood and the perception of discomfort. By blocking NK1 alongside NK3, Lynkuet was designed to address not just the flushes themselves but the sleep disruption and quality-of-life erosion that surround them. In the OASIS programme, improvements in sleep disturbance and menopause-related quality of life were measured as part of the trial design rather than treated as an incidental bonus.

That distinction speaks to a real clinical problem. Many women describe the night sweats as the more destructive symptom — not because the heat is worse, but because it fragments sleep for years. If sleep is the thing wrecking your life, our guide to [menopause insomnia](/blog/menopause-insomnia-why-you-cant-sleep-and-what-helps) covers the wider picture of why midlife sleep breaks down.

Both produce substantial, clinically meaningful reductions in hot flash frequency and severity. Lynkuet's headline numbers from OASIS are strong, but the honest answer is that the two have never been compared head-to-head.

In OASIS 1 and OASIS 2 — two randomised, double-blind, placebo-controlled trials enrolling 796 menopausal women — elinzanetant produced a 73.8% reduction in the frequency of moderate to severe vasomotor symptoms from baseline to week 12, compared with about 47% on placebo. OASIS 3 extended the safety and efficacy picture across 52 weeks.

The SKYLIGHT programme for fezolinetant likewise showed significant reductions in both the frequency and severity of moderate-to-severe VMS versus placebo, with separation from placebo appearing within the first weeks of treatment.

Two things are worth understanding about those numbers. First, the placebo response in hot flash trials is famously large — 40 to 50% is typical. That is not a flaw in the studies; hot flashes are genuinely responsive to expectation, attention and regression to the mean. The drug effect is the gap between the two arms, not the headline percentage.

Second, cross-trial comparison is not the same as a head-to-head trial. The OASIS and SKYLIGHT programmes enrolled different populations at different times with somewhat different endpoints. You cannot line up 73.8% against a SKYLIGHT figure and declare a winner. Anyone telling you one drug is definitively more effective than the other is going beyond what the evidence supports.

What both trials establish clearly is that these drugs work, that the effect is meaningful rather than marginal, and that onset is measured in weeks rather than months.

This is where the two drugs diverge most consequentially. Veozah carries an FDA boxed warning for liver injury and requires scheduled blood monitoring. Lynkuet does not.

In December 2024, the FDA added a boxed warning — the agency's most serious warning category — to Veozah for hepatotoxicity, following a postmarketing report of a patient who developed elevated liver enzymes along with signs and symptoms of liver injury. The label requires liver function testing before starting and at scheduled intervals during treatment, and instructs patients to stop the drug and seek care if they develop symptoms such as nausea, unusual fatigue, dark urine, pale stools, right upper abdominal pain, or yellowing of the skin or eyes.

By contrast, no cases of clinically apparent drug-induced liver injury were observed in the OASIS studies of elinzanetant, and Lynkuet was approved without an equivalent boxed warning.

A fair caveat: Veozah has been on the market since 2023 with substantial real-world exposure, and rare adverse events surface with volume and time. Lynkuet's postmarketing record is still short. Absence of a signal in trials is reassuring but not identical to a proven long-term safety advantage. Your prescriber will weigh both.

Beyond the liver, commonly reported side effects across the class include headache, fatigue, sleepiness or somnolence, and abdominal discomfort. Most are mild and settle in the first weeks.

Neither drug is appropriate for everyone. Both are contraindicated in pregnancy and in people with known cirrhosis or severe renal impairment, and both have drug interaction considerations — particularly with CYP1A2 inhibitors for fezolinetant. If you take other regular medications, that conversation with your prescriber or pharmacist is not optional.

Not automatically. For women who can safely take hormones, hormone therapy remains the most effective treatment for vasomotor symptoms and delivers benefits these drugs do not. The neurokinin antagonists are best understood as an excellent option for women for whom HRT is off the table — not as a replacement for it.

The difference is scope. Estrogen therapy treats hot flashes and night sweats, but it also helps preserve bone mineral density, treats genitourinary syndrome of menopause — the vaginal dryness, urinary urgency and painful sex that affect a large majority of postmenopausal women — and, when started within roughly ten years of the final period, is associated with a favourable cardiovascular profile in the timing hypothesis literature. Lynkuet and Veozah do none of that. They treat vasomotor symptoms. That is their job and they do it well, but the boundary is real.

Many women were steered away from hormones on the basis of the original 2002 Women's Health Initiative headlines, and the picture has been substantially revised since — we cover what the long-term data actually shows in [HRT and breast cancer risk](/blog/hrt-and-breast-cancer-risk-what-the-whi-data-actually-shows) and [how long you can stay on HRT](/blog/how-long-can-you-stay-on-hrt-duration-explained). If you ruled out hormones a decade ago on outdated advice, it is worth revisiting the question with a menopause-literate clinician before defaulting to a non-hormonal drug.

Where a neurokinin antagonist genuinely shines: a personal history of hormone-receptor-positive breast cancer; a history of venous thromboembolism or stroke; active liver disease that rules out oral estrogen; unexplained vaginal bleeding under investigation; or a clear, informed personal preference against hormones. In those situations these drugs represent a real advance over the previous non-hormonal menu of off-label SSRIs and gabapentin.

One more practical note: cost and coverage. Both drugs are brand-only with no generic, and insurance coverage varies considerably. Check your formulary and ask about manufacturer savings programmes before you assume the price on the shelf is the price you pay.